BREAKING: Target Test Prep releases Brand New 2026 On Demand GMAT prep course

Redeem

Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

★★★★★5.0559 reviews
Vote for Target Test Prep, Newsweek Readers’ Choice Awards 2026
NEWSWEEK READERS’ CHOICE 2026

BIG NEWS! Target Test Prep has been nominated, and they’d love your vote!

TTP has worked incredibly hard to build the best test prep experience possible, and winning Newsweek’s 2026 Readers’ Choice Award for Best Test Prep would mean a lot to them. If TTP has helped you, they’d be incredibly grateful for your vote. You can vote once each day through September 9.

Vote for TTP
GMATLiveTeach 7 seats left
Chris Peckover
NEXT LIVE COHORT

Oct 13 to Jan 7, 2027

with Chris Peckover

Schedule
Tue, Thu · 8:00 to 10:00 PM ET
Included
40 live hours + 6 months of GMAT OnDemand
  • Live instruction and real-time questions
  • Class recordings and assigned practice
View class & enroll
Limited cohort · enrollment openTarget Test Prep
EALiveTeach 5 seats left
Logan Thompson
EXECUTIVE ASSESSMENT

Sep 6 to Dec 6, 2026

with Logan Thompson

Schedule
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll
Limited cohort · enrollment openTarget Test Prep
GMATOnDemand Start anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Compare the format, schedule, and included access before enrolling. Prices and seat counts shown reflect the supplied offer details.

A CR question

Expert replies
by stormier » Wed Dec 08, 2010 8:34 am
The new drug Prozac and the old one Elavil are about equally effective in treating various forms of depression, although patients on the newer drug may have slightly fewer side effects. Thus, revenue from the sale of the new drug is going to far exceed the revenue from the sale of the old drug.

All of the following statements weaken the conclusion of the argument above, EXCEPT:

(A) Elavil is also used as a powerful anti-emetic medicine.

(B) The Drug Control Authorities in six states have refused to allow the sale of Prozac till some more tests are carried out.

(3) Some side effects of Elavil are common to Prozac as well.

(D) Prozac is not recommended as an anti-depressant for diabetics and heart patients.

(E) The unit sale price of Elavil is higher than that of Prozac.

Your Answer : E
Actual Answer : C

Explanation
The logic in the given argument is pretty weak : just because drug A is as effective as drug B for a particular cure, and has fewer side effects, does not mean that revenue from drug A is going to be more.
The old drug might still sell more if it has an alternate use (option A), or if sale of the new drug is not allowed in certain regions (option B), or if the new drug`s usage is restricted (option D), or if the sale price of drug B is higher (option E).
All these can be possible reasons for revenues from sale of drug B to be as high, or higher, from those of drug A.

Option C, however, offers no such reason, and is the right answer
.

Now is that correct explanation as provided ? I still think E is the right answer, because Prozac would sell more if Elavil's sale price is higher and thus it does not weaken the conclusion. Any comments.
Join the discussion
Source: — Critical Reasoning |

by rkanthilal » Wed Dec 08, 2010 9:53 am
stormier wrote:
Explanation
The logic in the given argument is pretty weak : just because drug A is as effective as drug B for a particular cure, and has fewer side effects, does not mean that revenue from drug A is going to be more.
The old drug might still sell more if it has an alternate use (option A), or if sale of the new drug is not allowed in certain regions (option B), or if the new drug`s usage is restricted (option D), or if the sale price of drug B is higher (option E).
All these can be possible reasons for revenues from sale of drug B to be as high, or higher, from those of drug A.

Option C, however, offers no such reason, and is the right answer.

Now is that correct explanation as provided ? I still think E is the right answer, because Prozac would sell more if Elavil's sale price is higher and thus it does not weaken the conclusion. Any comments.
Yes, I agree with the OE.

The conclusion is that revenue from the sale of the new drug (Prozac) is going to far exceed the revenue from the sale of the old drug (Elavil). This is based on the fact that both drugs are equally effective and Prozac has fewer side effects. This is a very strongly worded conclusion that is based on very few facts.

We need to choose the one answer that does not weaken the conclusion. The formula for revenue is:

REVENUE = (SALES PRICE) X (TOTAL UNITS SOLD)

Any answer choice that implies higher unit sales or a higher price for the drug Elavil will weaken the conclusion.

Answers (A), (B), and (D) imply higher unit sales while answer (E) specifically states that Elavil has a higher price. These answers weaken the conclusion by creating uncertainty. We can no longer say that one drug will have a higher revenue because we don't know the magnitude of these factors.

For example, answer (B) states that the authorities in six states have refused to allow the sale of Prozac. This will obviously hurt sales but will it decrease sales enough to result in Prozac generating lower revenue than Elavil. We don't know. We can't determine which drug will have the higher revenue. Since the conclusion is so strongly worded, introducing any amount of uncertainty weakens it.

Answer (E) states that "the unit sale price of Elavil is higher than that of Prozac." I believe your reasoning is that since a higher price results in lower sales, Prozac will sell more and thus generate more revenue.

In my opinion, this is incorrect for two reasons.

1) Even if a higher price results in lower unit sales, we don't know how the equation will play out. Similar to the other wrong answers, this answer creates uncertainty. A higher price may result in lower revenue or higher revenue. There is no way for us to know based on the information provided.

2) We can't assume that a higher price will lead to fewer sales. This is usually the case but there is nothing in the passage to suggest that this will happen. What if insurance covers the cost of the drug? Or, what if the higher price is only a few percentage points higher? In these cases the amount of sales may not be affected.
Join the discussion

by kapur.arnav » Wed Dec 08, 2010 10:05 am
stormier wrote:The new drug Prozac and the old one Elavil are about equally effective in treating various forms of depression, although patients on the newer drug may have slightly fewer side effects. Thus, revenue from the sale of the new drug is going to far exceed the revenue from the sale of the old drug.

All of the following statements weaken the conclusion of the argument above, EXCEPT:

(A) Elavil is also used as a powerful anti-emetic medicine.

(B) The Drug Control Authorities in six states have refused to allow the sale of Prozac till some more tests are carried out.

(3) Some side effects of Elavil are common to Prozac as well.

(D) Prozac is not recommended as an anti-depressant for diabetics and heart patients.

(E) The unit sale price of Elavil is higher than that of Prozac.

Your Answer : E
Actual Answer : C

Explanation
The logic in the given argument is pretty weak : just because drug A is as effective as drug B for a particular cure, and has fewer side effects, does not mean that revenue from drug A is going to be more.
The old drug might still sell more if it has an alternate use (option A), or if sale of the new drug is not allowed in certain regions (option B), or if the new drug`s usage is restricted (option D), or if the sale price of drug B is higher (option E).
All these can be possible reasons for revenues from sale of drug B to be as high, or higher, from those of drug A.

Option C, however, offers no such reason, and is the right answer
.

Now is that correct explanation as provided ? I still think E is the right answer, because Prozac would sell more if Elavil's sale price is higher and thus it does not weaken the conclusion. Any comments.
Maybe the price/tablet of Elavil is 100$ and Prozac 10$ and if 10 of Elavil and 90 of Prozac are sold .... Then Revenue from Prozac would be less than the revenue generated from Elavil... Hence C is better...
Join the discussion

by stormier » Wed Dec 08, 2010 10:36 am
Thanks guys, I guess I didn't realize the subtlety of sales (number) vs revenues. Aarg! Read the argument carefully is the lesson.
Join the discussion